About Zosano Pharma (NASDAQ:ZSAN)
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZSAN
CUSIPN/A
Phone510-745-1200
Debt
Debt-to-Equity RatioN/A
Current Ratio1.28%
Quick Ratio1.28%
Price-To-Earnings
Trailing P/E Ratio-0.25
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$310,000.00
Price / Sales161.40
Cash FlowN/A
Price / CashN/A
Book Value$3.57 per share
Price / Book1.17
Profitability
EPS (Most Recent Fiscal Year)($16.82)
Net Income$-29,100,000.00
Net MarginsN/A
Return on Equity-162.28%
Return on Assets-95.67%
Miscellaneous
Employees51
Outstanding Shares11,970,000
Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions
What is Zosano Pharma's stock symbol?
Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."
When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?
Zosano Pharma shares reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.
How were Zosano Pharma's earnings last quarter?
Zosano Pharma Corp (NASDAQ:ZSAN) posted its quarterly earnings data on Monday, March, 12th. The biotechnology company reported ($3.80) EPS for the quarter, beating analysts' consensus estimates of ($4.80) by $1.00. View Zosano Pharma's Earnings History.
When is Zosano Pharma's next earnings date?
Who are some of Zosano Pharma's key competitors?
Some companies that are related to Zosano Pharma include Menlo Therapeutics (MNLO), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA), Marinus Pharmaceuticals (MRNS), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Scpharmaceuticals (SCPH), Teligent (TLGT), Protagonist Therapeutics (PTGX), Zafgen (ZFGN), Evolus (EOLS), Sol Gel Technologies (SLGL), Spero Therapeutics (SPRO) and Spring Bank Pharmaceuticals (SBPH).
Who are Zosano Pharma's key executives?
Zosano Pharma's management team includes the folowing people:
- John P. Walker, Chairman of the Board, President, Chief Executive Officer (Age 68)
- Georgia L. Erbez, Interim Chief Financial Officer, Chief Business Officer (Age 49)
- Eric Scharin, Vice President - Technical Operations
- Thorsten von Stein M.D. Ph.D., Chief Medical Officer
- Joseph P. Hagan, Director (Age 48)
- Kenneth R. Greathouse, Independent Director
- Troy E. Wilson Ph.D. J.D., Independent Director (Age 48)
- Kleanthis G. Xanthopoulos Ph.D., Independent Director (Age 57)
When did Zosano Pharma IPO?
(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.
Has Zosano Pharma been receiving favorable news coverage?
News stories about ZSAN stock have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zosano Pharma earned a media sentiment score of 0.21 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 43.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Zosano Pharma's major shareholders?
Zosano Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include AISLING CAPITAL IV, LP (13.40%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc, Donald J Kellerman, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Kenneth Greathouse, Konstantinos Alataris and M James Barrett. View Institutional Ownership Trends for Zosano Pharma.
How do I buy shares of Zosano Pharma?
Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zosano Pharma's stock price today?
One share of ZSAN stock can currently be purchased for approximately $4.18.
How big of a company is Zosano Pharma?
Zosano Pharma has a market capitalization of $50.77 million and generates $310,000.00 in revenue each year. The biotechnology company earns $-29,100,000.00 in net income (profit) each year or ($16.82) on an earnings per share basis. Zosano Pharma employs 51 workers across the globe.
How can I contact Zosano Pharma?
Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]
MarketBeat Community Rating for Zosano Pharma (ZSAN)
MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma and other stocks. Vote "Outperform" if you believe ZSAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZSAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Zosano Pharma (NASDAQ:ZSAN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | Buy | Buy |
| Consensus Rating Score: | N/A | N/A | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | $70.00 | $70.00 |
| Price Target Upside: | N/A | N/A | 97.74% upside | 97.74% upside |
Zosano Pharma (NASDAQ:ZSAN) Consensus Price Target History
Zosano Pharma (NASDAQ:ZSAN) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Zosano Pharma (NASDAQ:ZSAN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Zosano Pharma (NASDAQ ZSAN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.83%
Zosano Pharma (NASDAQ ZSAN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/27/2018 | Amzak Capital Management, Llc | Major Shareholder | Sell | 88,281 | $8.40 | $741,560.40 | |  |
| 12/6/2017 | Kenneth Greathouse | Director | Buy | 55,000 | $0.61 | $33,550.00 | 200,000 | |
| 12/1/2017 | Kenneth Greathouse | Director | Buy | 95,000 | $0.62 | $58,900.00 | 95,000 | |
| 11/15/2017 | Kenneth Greathouse | Director | Buy | 50,000 | $0.62 | $31,000.00 | 35,000 | |
| 5/25/2017 | Georgia Erbez | CFO | Buy | 68,000 | $1.32 | $89,760.00 | 115,750 | |
| 5/25/2017 | John Peter Walker | CEO | Buy | 73,716 | $1.36 | $100,253.76 | 169,344 | |
| 2/13/2017 | Enterprise Associates 12 New | Major Shareholder | Sell | 1,099,996 | $2.01 | $2,210,991.96 | | |
| 9/16/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 7,471 | $0.75 | $5,603.25 | | |
| 9/13/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 10,000 | $0.74 | $7,400.00 | | |
| 8/29/2016 | M James Barrett | Major Shareholder | Sell | 50,000 | $1.01 | $50,500.00 | 5 | |
| 8/24/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 1,200 | $1.21 | $1,452.00 | | |
| 8/19/2016 | Donald J Kellerman | VP | Buy | 15,920 | $1.32 | $21,014.40 | 15,920 | |
| 8/19/2016 | Georgia Erbez | CFO | Buy | 47,750 | $1.32 | $63,030.00 | 47,750 | |
| 8/19/2016 | John Peter Walker | Director | Buy | 63,700 | $1.32 | $84,084.00 | 63,700 | |
| 8/19/2016 | Konstantinos Alataris | CEO | Buy | 127,389 | $1.32 | $168,153.48 | | |
| 7/21/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 23,681 | $1.27 | $30,074.87 | | |
| 7/13/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 13,382 | $1.20 | $16,058.40 | | |
| 1/30/2015 | Enterprise Associates 12 New | Major Shareholder | Buy | 23,457 | $11.00 | $258,027.00 | | |
(Data available from 1/1/2013 forward)
Zosano Pharma (NASDAQ ZSAN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zosano Pharma (ZSAN) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 16 at 7:35 PM |
| Zosano Pharma Corp (ZSAN) Expected to Announce Earnings of -$5.40 Per Share
www.americanbankingnews.com - April 13 at 3:12 AM |
 | Form 3 ELMS STEVE For: Mar 29 Filed by: Zosano Pharma Corp
www.streetinsider.com - April 10 at 9:01 AM |
| Zosano Pharma (ZSAN) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - April 9 at 4:05 PM |
 | Zosano Pharma's (ZSAN) Operational Update Conference Call (Transcript)
seekingalpha.com - April 5 at 10:46 AM |
| Zosano Pharma (ZSAN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 11:31 PM |
 | Here’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc
finance.yahoo.com - April 3 at 5:09 PM |
| Zosano Pharma closes $50M equity offering
seekingalpha.com - April 3 at 5:09 PM |
 | Zosano Pharma to Host Conference Call to Provide Operational Update
feeds.benzinga.com - April 2 at 1:52 PM |
| Zosano prices stock offering at $5; shares down 44%
seekingalpha.com - March 29 at 5:07 PM |
| Zosano Pharma (ZSAN) Prices 10 Million Share Offering at $5/Share
www.streetinsider.com - March 29 at 5:07 PM |
| Zosano Pharma readies stock offering; shares down 25% premarket
seekingalpha.com - March 29 at 8:55 AM |
| Zosano Pharma (ZSAN) Shares Decline on Concerns About Offering Price
www.streetinsider.com - March 29 at 8:55 AM |
| Zosano Pharma's stock plummets after stock offering filed, assumed to price at deep discount
finance.yahoo.com - March 29 at 8:55 AM |
| Zacks: Zosano Pharma Corp (ZSAN) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 28 at 7:32 PM |
| Zosano Pharma Corp (ZSAN) Expected to Post Earnings of -$5.40 Per Share
www.americanbankingnews.com - March 27 at 3:04 AM |
| Zosano Pharma (ZSAN) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 12:52 AM |
| Wired News – Zosano Reports Enrollment Milestone in its M207-ADAM Study
finance.yahoo.com - March 20 at 8:58 AM |
| Zosano Pharma (ZSAN) Announced 100th Patient Enrolled in M207-ADAM Migraine Study
www.streetinsider.com - March 16 at 6:05 PM |
| Should You Buy Zosano Pharma Corporation (NASDAQ:ZSAN) Now?
finance.yahoo.com - March 16 at 6:05 PM |
| Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study
finance.yahoo.com - March 16 at 8:52 AM |
| Zosano Pharma (ZSAN) Issues Earnings Results
www.americanbankingnews.com - March 13 at 10:56 AM |
 | Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update - GlobeNewswire (press release)
globenewswire.com - March 12 at 6:13 PM |
| Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update
finance.yahoo.com - March 12 at 12:20 PM |
| -$4.80 EPS Expected for Zosano Pharma Corp (ZSAN) This Quarter
www.americanbankingnews.com - March 9 at 9:30 PM |
| Zosano Pharma set to add to rally, up 20% premarket
seekingalpha.com - March 9 at 6:17 PM |
| The Market In 5 Minutes: Trump And Kim Jung Un, Toys 'R' Us Liquidation, Zosano's Move, Big Payrolls Beat
finance.yahoo.com - March 9 at 6:17 PM |
| 36 Stocks Moving In Friday's Mid-Day Session
feeds.benzinga.com - March 9 at 2:43 PM |
 | Zosano Pharma Is The Latest Low Float Stock To Make A Huge Move
www.msn.com - March 8 at 6:10 PM |
| Report: Developing Opportunities within Owens & Minor, Zosano Pharma, Organovo, Summit Materials, Ralph Lauren, and Clearside Biomedical — Future Expectations, Projections Moving into 2018
finance.yahoo.com - March 8 at 8:52 AM |
| Zosano Pharma Corp (ZSAN) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 8 at 5:38 AM |
| 31 Stocks Moving In Wednesday's Mid-Day Session
feeds.benzinga.com - March 7 at 2:12 PM |
| Zosano Pharma Corp (ZSAN) Given $80.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 3 at 5:16 PM |
| Zosano Pharma (ZSAN) Announces Issuance of New U.S. Patent Covering M207
www.streetinsider.com - March 2 at 5:45 PM |
| Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine
finance.yahoo.com - March 2 at 8:41 AM |
| Zosano Pharma Corp (ZSAN) Major Shareholder Sells $741,560.40 in Stock
www.americanbankingnews.com - February 28 at 6:16 PM |
| Today’s Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Zosano Pharma
finance.yahoo.com - February 27 at 8:45 AM |
| Zosano Pharma Corp (ZSAN) Expected to Announce Earnings of -$4.80 Per Share
www.americanbankingnews.com - February 21 at 5:24 AM |
| Zosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:30 AM |
 | ETF Preview: ETFs, Futures Point to Modest Gains Following CPI, Retail Sales Data
www.nasdaq.com - February 14 at 9:37 AM |
| Zosano Pharma up 34% premarket ahead of stock offering
seekingalpha.com - February 14 at 9:37 AM |
 | Stock Review for Biotech's Investors -- Spark Therapeutics, Synthetic Biologics, TG Therapeutics, and Zosano Pharma
www.bizjournals.com - February 6 at 9:34 AM |
| Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split
finance.yahoo.com - January 25 at 9:39 AM |
| -$0.24 EPS Expected for Zosano Pharma Corp (ZSAN) This Quarter
www.americanbankingnews.com - January 18 at 5:06 AM |
| Analysts Expect Zosano Pharma Corp (ZSAN) to Announce ($0.24) EPS
www.americanbankingnews.com - January 13 at 5:06 PM |
| Zosano Pharma (ZSAN) Announces Notice of Allowance for US Patent Application Covering M207 as Acute Treatment ... - StreetInsider.com
www.streetinsider.com - January 3 at 4:24 PM |
| Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine
finance.yahoo.com - January 3 at 9:47 AM |
| Want To Invest In Zosano Pharma Corporation (NASDAQ:ZSAN)? Here’s How It Performed Lately
finance.yahoo.com - January 2 at 5:05 PM |
| Zosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - January 1 at 11:22 AM |
| Zosano Pharma (ZSAN) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - December 31 at 11:04 PM |
Zosano Pharma (NASDAQ:ZSAN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Zosano Pharma (NASDAQ:ZSAN) Income Statement, Balance Sheet and Cash Flow Statement
Zosano Pharma (NASDAQ ZSAN) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
